Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo Bioworks Holdings, Inc. filed a Form 8-K dated November 15, 2021, under Items 2.02 and 9.01. The filing announces the release of financial results for the third quarter ended September 30, 2021. Ginkgo’s Class A common stock and warrants traded on the NYSE under the symbols DNA and DNA.WS, respectively.
Financial metrics
The filing text provided does not include revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial figures. The related earnings press release was furnished as Exhibit 99.1, but its contents are not included in the provided filing text.
Material changes versus the prior comparable period
The provided filing text does not describe year-over-year or sequential changes in operating or financial performance.
Guidance, outlook, risks, and unusual items
No guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the provided filing text. Item 2.02 information, including Exhibit 99.1, was furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference except where expressly stated.
Important facts to verify
- Review Exhibit 99.1 for the complete third-quarter 2021 financial results and management commentary.
- Verify reported revenue, net loss or income, adjusted metrics, cash balance, cash burn, debt, and liquidity.
- Check any full-year guidance, operating targets, and comparisons with the third quarter of 2020 and the preceding quarter.
- Assess disclosures regarding COVID-19 testing or other programs, customer concentration, contingencies, and unusual items, if addressed in the press release.